middle.news
PYC Therapeutics Advances RNA Pipeline with Phase 1b Dose Escalations and $669m Cash Reserve
8:45am on Wednesday 29th of July, 2026 AEST
•
Biotechnology
Read Story
PYC Therapeutics Advances RNA Pipeline with Phase 1b Dose Escalations and $669m Cash Reserve
8:45am on Wednesday 29th of July, 2026 AEST
Key Points
Phase 1b dose escalation approved in PKD program
Orphan Drug Designation granted for RP11 candidate
Sustained visual improvements reported in ADOA trials
Phelan-McDermid Syndrome program advancing preclinical studies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE